JP2010523541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523541A5 JP2010523541A5 JP2010501612A JP2010501612A JP2010523541A5 JP 2010523541 A5 JP2010523541 A5 JP 2010523541A5 JP 2010501612 A JP2010501612 A JP 2010501612A JP 2010501612 A JP2010501612 A JP 2010501612A JP 2010523541 A5 JP2010523541 A5 JP 2010523541A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 176
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102000016359 Fibronectins Human genes 0.000 claims 7
- 108010067306 Fibronectins Proteins 0.000 claims 7
- 206010027476 Metastases Diseases 0.000 claims 6
- 230000009401 metastasis Effects 0.000 claims 6
- 102000001708 Protein Isoforms Human genes 0.000 claims 5
- 108010029485 Protein Isoforms Proteins 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000004602 germ cell Anatomy 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90958007P | 2007-04-02 | 2007-04-02 | |
| US60/909,580 | 2007-04-02 | ||
| US94856407P | 2007-07-09 | 2007-07-09 | |
| US60/948,564 | 2007-07-09 | ||
| PCT/IB2008/000965 WO2008120101A2 (en) | 2007-04-02 | 2008-03-31 | The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013006880A Division JP5840631B2 (ja) | 2007-04-02 | 2013-01-18 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523541A JP2010523541A (ja) | 2010-07-15 |
| JP2010523541A5 true JP2010523541A5 (enExample) | 2012-11-15 |
| JP5221641B2 JP5221641B2 (ja) | 2013-06-26 |
Family
ID=39791007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501612A Expired - Fee Related JP5221641B2 (ja) | 2007-04-02 | 2008-03-31 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
| JP2013006880A Active JP5840631B2 (ja) | 2007-04-02 | 2013-01-18 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013006880A Active JP5840631B2 (ja) | 2007-04-02 | 2013-01-18 | 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US8263041B2 (enExample) |
| EP (2) | EP2653478B1 (enExample) |
| JP (2) | JP5221641B2 (enExample) |
| KR (1) | KR101515243B1 (enExample) |
| CN (2) | CN101687923B (enExample) |
| AU (1) | AU2008234615B2 (enExample) |
| BR (1) | BRPI0809989B8 (enExample) |
| CA (1) | CA2682851C (enExample) |
| EA (2) | EA036322B1 (enExample) |
| ES (2) | ES2609813T3 (enExample) |
| MX (1) | MX2009010639A (enExample) |
| WO (1) | WO2008120101A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2817005B2 (ja) | 1990-06-29 | 1998-10-27 | スズキ株式会社 | エンジン用オーバヒート検出装置 |
| CA2682851C (en) | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| US10202442B2 (en) * | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| EA017995B1 (ru) * | 2007-07-25 | 2013-04-30 | Филоджен С.П.А. | Антиген, связанный с вариантами рака легкого и лимфомами |
| EP2209805B1 (en) * | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| WO2010078945A2 (en) | 2009-01-07 | 2010-07-15 | Philogen S.P.A. | Cancer treatment |
| EP2379116B1 (en) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| WO2011156639A1 (en) * | 2010-06-10 | 2011-12-15 | The Regents Of The University Of California | Eiiia and eiiib segments of fibronectin regulate stem cell fate |
| JP5548872B2 (ja) * | 2010-08-26 | 2014-07-16 | 株式会社島津製作所 | 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法 |
| EP3842074A1 (en) | 2010-09-29 | 2021-06-30 | Philogen S.p.A. | Protein-drug conjugates |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| EP2903629B1 (en) | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| SG10201805706XA (en) | 2013-12-12 | 2018-08-30 | Umc Utrecht Holding Bv | Immunoglobulin-like molecules directed against fibronectin-eda |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| RU2018105687A (ru) | 2015-07-16 | 2019-08-16 | Филоджен С.П.А. | Иммуноконъюгаты на основе il22 |
| IL310865A (en) | 2016-10-17 | 2024-04-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| EP3634999A1 (en) | 2017-06-07 | 2020-04-15 | Philogen S.p.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| CN114206355A (zh) * | 2019-06-03 | 2022-03-18 | 芝加哥大学 | 用靶向癌症的佐剂治疗癌症的方法和组合物 |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| TW202120537A (zh) | 2019-08-15 | 2021-06-01 | 美商健生生物科技公司 | 用於經改善的單鏈可變片段之材料及方法 |
| EP4185615A1 (en) | 2020-07-22 | 2023-05-31 | Philogen S.p.A. | Treatment of pulmonary hypertension |
| CN114350518B (zh) * | 2022-01-19 | 2023-01-13 | 广东乾晖生物科技有限公司 | 仿生肝微流控细胞培养-药物筛选芯片 |
| US20250197485A1 (en) | 2022-03-17 | 2025-06-19 | Universitätsklinikum Jena | Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| FI892197A7 (fi) * | 1989-05-08 | 1990-11-09 | Locus Oy | Foerfarande foer detektering av tumoerer. |
| US5420012A (en) | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| WO1992017604A1 (fr) * | 1991-03-26 | 1992-10-15 | Otsuka Pharmaceutical Factory, Inc. | Anticorps monoclonal anti-eda |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US8623373B2 (en) | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| CA2404919A1 (en) | 2000-04-06 | 2002-10-01 | Kyowa Hakko Kogyo Co. Ltd. | Diagnostic and therapeutic agents for rheumatoid arthritis |
| AU5867901A (en) | 2000-05-04 | 2001-11-12 | Philogen S.R.L. | Method for detecting tumors |
| US20020197700A1 (en) | 2000-09-07 | 2002-12-26 | Schering Ag | Receptor of the EDb-fibronectin domains |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| PL369371A1 (en) * | 2002-01-03 | 2005-04-18 | Schering Aktiengesellschaft | New methods for diagnosis and treatment of tumours |
| WO2004000216A2 (en) | 2002-06-21 | 2003-12-31 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| CA2523452A1 (en) | 2003-04-22 | 2004-11-04 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| EP1660519B1 (en) | 2003-07-29 | 2014-05-14 | Immunomedics, Inc. | Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule |
| US20060024722A1 (en) | 2004-07-30 | 2006-02-02 | Mark Fischer-Colbrie | Samples for detection of oncofetal fibronectin and uses thereof |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| SI1817345T1 (sl) | 2004-11-09 | 2009-10-31 | Philogen Spa | Protitelesa proti tenascinu-C |
| MX2007013875A (es) | 2005-05-11 | 2008-01-28 | Philogen Spa | Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12. |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| CA2682851C (en) * | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| EA017995B1 (ru) | 2007-07-25 | 2013-04-30 | Филоджен С.П.А. | Антиген, связанный с вариантами рака легкого и лимфомами |
| EP2209805B1 (en) * | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| EP2379116B1 (en) * | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| EP3842074A1 (en) * | 2010-09-29 | 2021-06-30 | Philogen S.p.A. | Protein-drug conjugates |
| ES2872964T3 (es) * | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| EP2988784A1 (en) * | 2013-04-25 | 2016-03-02 | Philogen S.p.A. | Antibody-drug conjugates |
| JP2016519111A (ja) * | 2013-04-26 | 2016-06-30 | フィロゲン エスピーエー | 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４ |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2008
- 2008-03-31 CA CA2682851A patent/CA2682851C/en active Active
- 2008-03-31 CN CN2008800183109A patent/CN101687923B/zh active Active
- 2008-03-31 CN CN201310167446.9A patent/CN103275220B/zh active Active
- 2008-03-31 EP EP12195343.4A patent/EP2653478B1/en active Active
- 2008-03-31 EA EA201301224A patent/EA036322B1/ru not_active IP Right Cessation
- 2008-03-31 US US12/593,872 patent/US8263041B2/en active Active
- 2008-03-31 EA EA200970909A patent/EA018985B1/ru not_active IP Right Cessation
- 2008-03-31 EP EP08737486A patent/EP2142567B1/en not_active Not-in-force
- 2008-03-31 WO PCT/IB2008/000965 patent/WO2008120101A2/en not_active Ceased
- 2008-03-31 MX MX2009010639A patent/MX2009010639A/es active IP Right Grant
- 2008-03-31 ES ES12195343.4T patent/ES2609813T3/es active Active
- 2008-03-31 ES ES08737486T patent/ES2402171T3/es active Active
- 2008-03-31 BR BRPI0809989A patent/BRPI0809989B8/pt not_active IP Right Cessation
- 2008-03-31 JP JP2010501612A patent/JP5221641B2/ja not_active Expired - Fee Related
- 2008-03-31 AU AU2008234615A patent/AU2008234615B2/en active Active
- 2008-03-31 KR KR1020097022770A patent/KR101515243B1/ko active Active
-
2012
- 2012-08-09 US US13/570,945 patent/US8481684B2/en active Active
-
2013
- 2013-01-18 JP JP2013006880A patent/JP5840631B2/ja active Active
- 2013-06-06 US US13/911,815 patent/US20130266511A1/en not_active Abandoned
- 2013-07-03 US US13/935,171 patent/US9181347B2/en active Active
-
2015
- 2015-10-05 US US14/874,923 patent/US9896503B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534237A5 (enExample) | ||
| RU2010121874A (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| JP2013121353A5 (enExample) | ||
| JP2011502137A5 (enExample) | ||
| HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| NZ603529A (en) | Antibodies to human gdf8 | |
| AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| HRP20180015T1 (hr) | Anti-mezotelinski imunokonjugati i njihova uporaba | |
| JP2014511179A5 (enExample) | ||
| JP2017530092A5 (enExample) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2012521217A5 (enExample) | ||
| WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| JP2017522861A5 (enExample) | ||
| NZ594480A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| ME02798B (me) | Protutijela protiv dkk-1" |